GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Golden Biotechnology Corp (ROCO:4132) » Definitions » EV-to-EBIT

Golden Biotechnology (ROCO:4132) EV-to-EBIT : -10.26 (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Golden Biotechnology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Golden Biotechnology's Enterprise Value is NT$3,638.50 Mil. Golden Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-354.62 Mil. Therefore, Golden Biotechnology's EV-to-EBIT for today is -10.26.

The historical rank and industry rank for Golden Biotechnology's EV-to-EBIT or its related term are showing as below:

ROCO:4132' s EV-to-EBIT Range Over the Past 10 Years
Min: -85.34   Med: -15.5   Max: -8.32
Current: -10.26

During the past 13 years, the highest EV-to-EBIT of Golden Biotechnology was -8.32. The lowest was -85.34. And the median was -15.50.

ROCO:4132's EV-to-EBIT is ranked worse than
100% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs ROCO:4132: -10.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Golden Biotechnology's Enterprise Value for the quarter that ended in Dec. 2023 was NT$5,700.79 Mil. Golden Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-354.62 Mil. Golden Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -6.22%.


Golden Biotechnology EV-to-EBIT Historical Data

The historical data trend for Golden Biotechnology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Golden Biotechnology EV-to-EBIT Chart

Golden Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.02 -16.34 -40.72 -31.00 -16.08

Golden Biotechnology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.72 - -31.00 - -16.08

Competitive Comparison of Golden Biotechnology's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Golden Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Golden Biotechnology's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Golden Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Golden Biotechnology's EV-to-EBIT falls into.



Golden Biotechnology EV-to-EBIT Calculation

Golden Biotechnology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3638.495/-354.618
=-10.26

Golden Biotechnology's current Enterprise Value is NT$3,638.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Golden Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-354.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Golden Biotechnology  (ROCO:4132) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Golden Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-354.618/5700.78655
=-6.22 %

Golden Biotechnology's Enterprise Value for the quarter that ended in Dec. 2023 was NT$5,700.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Golden Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-354.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Golden Biotechnology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Golden Biotechnology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Golden Biotechnology (ROCO:4132) Business Description

Traded in Other Exchanges
N/A
Address
15F, No. 27-6, Sec. 2, Chung Cheng East Road, Danshuie Township, Taipei, TWN, 251
Golden Biotechnology Corp is a Taiwan based company engages in the production of drugs and herbal supplement. It specializes in anti-cancer and anti-atherosclerosis drugs.

Golden Biotechnology (ROCO:4132) Headlines

No Headlines